Latest Capital Raises News

Botanix Pharmaceuticals reports a surge in Sofdra sales driving revenue to $16.5 million, yet the company records a $33.2 million loss amid expanded marketing and operational costs. A $45 million capital raise aims to support growth and supply chain improvements.

I Synergy Group Limited reported a 15.63% drop in revenue to AUD 0.81 million for FY2025, alongside a 21.5% increase in net loss to AUD 0.34 million, with auditors flagging going concern uncertainties.

CONNEQT Health reported a 40% revenue increase to $2.28 million for the half-year ending December 2025, driven by strong sales of its CONNEQT Pulse device and early subscription uptake. Despite narrowing its net loss by 14%, the company continues to navigate operational restructuring and funding challenges as it pivots towards a recurring revenue model.

Skin Elements Limited reported a $4.01 million loss for the half-year ending December 2025, alongside a 41% revenue drop, while securing $2.5 million in fresh capital to advance its proprietary SE Formula biotechnology products.

Burgundy Diamond Mines reported a net loss of $86.8 million for 2025, reflecting operational challenges including the suspension of Point Lake mining due to adverse tariffs. The company secured $83.4 million in Canadian tariff relief financing to bolster liquidity and restructured its debt amid ongoing market uncertainties.

PainChek Limited reported a half-year loss of AUD 4.7 million but achieved a major regulatory milestone with FDA clearance for its Adult App, unlocking significant US market opportunities. The company also completed a share consolidation and raised capital to support growth.

DigitalX Limited reported a narrower half-year loss and increased revenues, underpinned by a strategic pivot to a Bitcoin-first treasury model and operational cost discipline.

NoviqTech Limited reported a widening loss of $2.83 million for 2025, alongside a severe drop in cash reserves and a looming going concern uncertainty flagged in its upcoming audit.

Radiopharm Theranostics reported a 44% increase in net loss to $27 million for the half-year ended December 2025, driven by expanded R&D spending. The company bolstered its cash reserves through a $35 million placement while progressing multiple clinical trials across its radiopharmaceutical pipeline.

RocketBoots Limited reported a steep 71.75% drop in profit after tax to a $2.36 million loss for the half-year ending December 2025, despite a modest revenue increase. The company’s future hinges on a transformative $9.1 million annual recurring revenue contract with a tier-one multinational retailer and a recent $7 million capital raise.

Racura Oncology reported a $4.1 million loss for H1 FY26, reflecting heavy investment in clinical trials and intellectual property. The company also boosted cash reserves through capital raises and rebranded from Race Oncology.

Thrive Tribe Technologies reported a $1.8 million half-year loss, driven by a major software impairment and ongoing operational challenges, while raising over $1.5 million in fresh capital to support its evolving business model.